Novartis AG (SWX:NOVN)
126.60
-0.18 (-0.14%)
Jul 31, 2026, 5:30 PM CET
Novartis AG Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 56,693 | 56,674 | 51,722 | 46,660 | 43,461 | 43,974 |
Revenue Growth | 2.73% | 9.57% | 10.85% | 7.36% | -1.17% | -11.87% |
Gross Profit Gross Profit Growth | 42,506 | 43,054 | 38,907 | 34,188 | 31,879 | 32,583 |
Operating Income Operating Income Growth | 18,568 | 19,005 | 16,320 | 10,234 | 9,213 | 10,963 |
Net Income Net Income Growth | 12,757 | 13,984 | 11,941 | 14,850 | 6,955 | 24,021 |
Earnings Per Share EPS Growth | 6.61 | 7.15 | 5.87 | 7.10 | 3.17 | 10.63 |
EPS Growth | -3.43% | 21.81% | -17.36% | 123.90% | -70.16% | 202.06% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cardiovascular, Renal And Metabolic Cardiovascular, Renal And Metabolic Growth | 7,247 | 8,959 | 8,576 | 6,390 | 4,756 | 3,560 |
Immunology Immunology Growth | 10,581 | 10,293 | 9,293 | 7,798 | 7,287 | 7,205 |
Neuroscience Neuroscience Growth | 6,672 | 5,993 | 4,750 | 3,651 | 3,038 | 5,007 |
Oncology Oncology Growth | 17,167 | 16,830 | 14,297 | 12,851 | 11,176 | 10,531 |
Established Brands Established Brands Growth | 13,099 | 12,457 | 13,401 | 14,750 | 15,949 | 12,241 |
Revenue (Total) Revenue (Total) Growth | 56,693 | 56,674 | 51,722 | 46,660 | 43,461 | 43,974 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 7,618 | 11,533 | 13,351 | 14,073 | 18,726 | 28,224 |
Total Debt Total Debt Growth | 49,014 | 35,457 | 31,401 | 26,439 | 27,964 | 31,093 |
Net Cash (Debt) Net Cash Growth | -41,396 | -23,924 | -18,050 | -12,366 | -9,238 | -2,869 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -21.48 | -12.24 | -8.87 | -5.91 | -4.20 | -1.27 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 18,393 | 19,144 | 17,619 | 14,458 | 14,236 | 15,071 |
Capital Expenditures CapEx Growth | -1,630 | -1,548 | -1,366 | -1,060 | -916 | -1,066 |
Free Cash Flow Free Cash Flow Growth | 16,763 | 17,596 | 16,253 | 13,398 | 13,320 | 14,005 |
Free Cash Flow Growth | -13.25% | 8.26% | 21.31% | 0.59% | -4.89% | 13.17% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 74.98% | 75.97% | 75.22% | 73.27% | 73.35% | 74.10% |
Operating Margin | 32.75% | 33.53% | 31.55% | 21.93% | 21.20% | 24.93% |
Pretax Margin | 27.38% | 28.85% | 26.37% | 19.55% | 16.51% | 55.78% |
Profit Margin | 22.50% | 24.67% | 23.09% | 31.83% | 16.00% | 54.63% |
FCF Margin | 29.57% | 31.05% | 31.42% | 28.71% | 30.65% | 31.85% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 3.700 | 4.666 | 3.862 | 3.919 | 3.461 | 3.401 |
Dividend Per Share Growth | 5.71% | 20.81% | -1.44% | 13.24% | 1.77% | 0.29% |
Dividend Yield | 2.92% | 3.48% | 4.21% | 4.31% | 4.66% | 4.90% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 23.69 | 18.97 | 16.39 | 13.95 | 27.96 | 8.20 |
Forward PE | 17.24 | 16.13 | 11.74 | 13.86 | 14.41 | 13.15 |
P/FCF Ratio | 17.77 | 15.07 | 12.04 | 15.46 | 14.60 | 14.07 |
PS Ratio | 5.25 | 4.68 | 3.78 | 4.44 | 4.47 | 4.48 |